Curis

Lexington, United States Founded: 2000 • Age: 26 yrs Listed
Therapeutics are developed by targeting signaling pathways for multiple cancers.

About Curis

Curis is a publicly listed company based in Lexington (United States) founded in 2000. Therapeutics are developed by targeting signaling pathways for multiple cancers. It operates on a Professional Services model. The company has 34 employees. Curis offers products and services including Emavusertib (CA-4948), Fimepinostat, Erivedge, CA-170, and CA-327. Its focus areas include Biotechnology and Cancer Therapeutics. Its legal entity is Curis, Inc. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.

Company details

Curis, Inc. is engaged in the development and commercialization of differentiated therapeutics aimed at improving the lives of cancer patients. The companys efforts are centered on hematologic malignancies and other cancer types. Key programs include Emavusertib for leukemia and lymphoma, Fimepinostat for MYC-altered cancers, and Erivedge for basal cell carcinoma. Research and clinical activities are supported through collaborations and intellectual property licensing with partners like Aurigene and Genentech. The companys pipeline spans preclinical to commercial stages, addressing critical needs in oncology.

  • Headquarters Lexington, United States
  • Employees 34
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website curis.com
  • Social LinkedIn X
  • Legal Name Curis, Inc.
Operational Areas
Key Metrics
  • Annual Revenue
    $9.44 M (USD)
    -13.43
    as on Dec 31, 2025
  • Net Profit
    -$7.58 M (USD)
    82.53
    as on Dec 31, 2025
  • EBITDA
    -$32.73 M (USD)
    25.16
    as on Dec 31, 2025
  • Latest Funding Round
    $45M (USD), Debt – Conventional

    Apr 2017

  • Investors
    Genentech

    & 2 more

  • Employee Count
    34

Products & Services of Curis

Curis offers a comprehensive portfolio of products and services, including Emavusertib (CA-4948), Fimepinostat, Erivedge, CA-170, and CA-327.

Emavusertib (CA-4948)
Therapeutics

Developed for treating hematologic malignancies like leukemia and lymphoma.

Fimepinostat
Therapeutics

Targeted for MYC-altered cancers in clinical activity stage.

Erivedge
Therapeutics

Approved drug for treating basal cell carcinoma commercially.

CA-170
Therapeutics

Developed for PDL1/VISTA-expressing cancers in clinical stage.

CA-327
Therapeutics

Focused on PDL1/TIM3-expressing cancers at proof stage.

Funding Insights of Curis

  • Total Rounds 6
  • Last Round Debt – Conventional β€” $45M
  • Investors Count 3

All 6 funding rounds of Curis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2017$45MDebt – Conventional––
Mar 2015$64.7MPost-IPO––
–
Dec 2012$30MDebt – Venture––
May 2012$964,000Post-IPO––
–
Nov 2010$500,000Grant––
–
Apr 2005Post-IPO––
Valuation history

3 investors in total: 3 institutional.

Investors in Curis

Curis has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Genentech, HealthCare Royalty Partners and Pharmakon Advisors.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Healthcare royalty investments are focused on US and UK markets.
healthcareroyalty.comStamford, United States
Investment management services are provided to the life sciences industry.
pharmakonadvisors.comNew York, United States
R&D company focused on manufacturing drugs for multiple therapeutic areas
1976gene.comSan Francisco, United States
Premium access

Investor details for Curis

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Curis

19 people are tracked at Curis (9 in leadership, 5 in board & advisors, 5 in team); the tracked headcount is 34.

NameRoleGroup
Bill Steinkrauss
CFOLeadership
James Dentzer
President & CEOLeadership
Elizabeth Martinez
Executive Director Of Global Medical Affairs At CurisLeadership
Jonathan Zung
Chief Development Officer (cdo)Leadership
Kristopher Lake
Senior Director, Business Planning & AnalysisLeadership
Diantha Duvall
Chief Financial OfficerLeadership
Rachel Blasbalg (Klein)
Senior Director Human ResourcesLeadership
Frank Waligora
Vp, Technical OperationsLeadership
Jamison Hoffman Pharmd
Senior Director, Medical AffairsLeadership
Martyn D. Greenacre
Chair of the BoardBoard & advisors
Kenneth I. Kaitin
Board MemberBoard & advisors
Lori A. Kunkel
Board MemberBoard & advisors
Marc Rubin
Board MemberBoard & advisors
John Hohneker
Board MemberBoard & advisors
Jennifer Wagner
Sr. Manager, Human ResourcesTeam
Sheila Murphy
Assistant ControllerTeam
Rose Cusella
Assistant ControllerTeam
Randolph Noelle
SABTeam
Kayli Walker
Accounting ManagerTeam
Premium access

Complete people profiles for Curis

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Curis

Curis is a publicly listed company on the NASDAQ with ticker symbol CRIS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date04 Aug 2000
  • Listed onNASDAQ: CRIS
  • Listed entityCuris, Inc.
  • Exchange sectorHealth technology
  • ISINUS2312694084
  • Share price$0.61 (-4.41% on the day) · 2026-10-13
  • Market capitalisation$1.3M
  • EPS (diluted, trailing year)$-14.29
  • Volume (last session)213,084

Financials of Curis

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$9.4M-$7.6M-$32.7M
2024$10.9M-$43.4M-$43.7M
2023$10.0M-$47.4M-$48.1M
2022$10.2M-$56.7M-$51.6M
2021$10.7M-$45.4M-$41.1M
Premium access

Detailed financial statements for Curis

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Curis

4 dated milestones of Curis across 17 years, from founding to its latest funding, stage changes and deals.

  1. Founded Curis is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round.
  4. Funding Latest funding round, Debt – Conventional, of $45.0M.

Competitors of Curis

Curis has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
modernatx.com2010Cambridge, United States$2.78B1,312
mRNA-based therapeutics for diseases including cancer and infections are developed.
beigene.com2010Cambridge, United States$172M1,090
Targeted and immune-oncology drugs for cancer treatment are developed.
incyte.com1991Wilmington, United States1,387
Small molecules are developed for cancer and skin disease treatments.
Premium access

Detailed competitors of Curis

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Curis

The website of Curis (curis.com) receives about 4.8K visits a month and ranks #3,916,131 among all websites worldwide, #4,962 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    4.8K

    ▼ 4.4% vs previous month

  • Unique visitors
    2.2K

    per month

  • Global rank
    #3,916,131

    among all websites

  • Category rank
    #4,962

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Curis. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
investor.seattlegenetics.com
investor.seattlegenetics.com
100%
–
ctibiopharma.com
92%
View details
xencor.com
91%
22.2K#2,563,685View details
optimerpharma.com
91%
View details
gemacbio.com
gemacbio.com
91%
–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 15 similar websites and full traffic analytics for Curis

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 15 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Oncology

3 companies that operate in the same segment as Curis (Oncology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Curis

Premium access

Complete news archive for Curis

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Curis

Curis was founded in 2000 and raised its 1st funding round 5 years after it was founded.

Curis is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.

Curis has 34 employees.

Annual revenue of Curis is $9.44M as on Dec 31, 2025.

Curis, Inc. is engaged in the development and commercialization of differentiated therapeutics aimed at improving the lives of cancer patients. The companys efforts are centered on hematologic malignancies and other cancer types. Key programs include Emavusertib for leukemia and lymphoma, Fimepinostat for MYC-altered cancers, and Erivedge for basal cell carcinoma. Research and clinical activities are supported through collaborations and intellectual property licensing with partners like Aurigene and Genentech. The companys pipeline spans preclinical to commercial stages, addressing critical needs in oncology.

Curis's top competitors include Moderna, BeiGene and Incyte.

Curis offers Emavusertib (CA-4948), Fimepinostat, Erivedge, CA-170, and CA-327.

Yes, Curis is publicly traded on NASDAQ under the ticker symbol CRIS.

Curis has 3 investors. Key investors include Genentech, HealthCare Royalty Partners, and Pharmakon Advisors.

Curis operates through Curis, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available